| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $309,372,246 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | UF1MH135901 | Developing Data-Driven Clinical Signatures for People Who Experience Hallucinations | 000 | 3 | NIH | 4/23/2026 | $7,182,142 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R21AR085967 | Inflammatory cell death in systemic lupus erythematosus | 000 | 1 | NIH | 4/22/2026 | $412,569 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | K23AR086325 | Tailored Exercise Interventions for Patients with Axial Spondyloarthritis: Targeting Sex-Based Challenges to Improve Clinical Outcomes | 000 | 1 | NIH | 6/23/2026 | $169,668 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | K01AI190049 | Enhancing Influenza Vaccines through Genetic Surveillance: Can Better Antigenic Match Improve Population Health? | 000 | 1 | NIH | 3/30/2026 | $182,422 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R13HL186682 | Research Priorities in Stimulant-Associated Cardiopulmonary Disease | 000 | 1 | NIH | 7/6/2026 | $15,000 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01AR082814 | Expression of dystrophins with enhanced function | 001 | 2 | NIH | 5/14/2026 | $34,978 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01AR082814 | Expression of dystrophins with enhanced function | 000 | 2 | NIH | 1/6/2026 | $629,584 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01GM163162 | Tissue transcriptomics enabled by spectral binary barcodes | 000 | 1 | NIH | 4/7/2026 | $2,102,360 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01CA300695 | Stratifying Underlying Risk in the Prostate cancer Active Surveillance Study (SURPASS) | 000 | 1 | NIH | 3/24/2026 | $688,959 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R21NS149049 | Identification of axon length-dependent gene expression programs | 000 | 1 | NIH | 5/19/2026 | $427,625 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R21NR021756 | Study Assessing Feasibility and Effectiveness of Community-Based Heart Failure Care (SAFE-HF)) | 000 | 1 | NIH | 5/14/2026 | $308,138 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | F31DA065365 | Serotonin and dopamine dynamics during kappa opioid mediated aversion | 002 | 1 | NIH | 3/25/2026 | $576 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | F31DA065365 | Serotonin and dopamine dynamics during kappa opioid mediated aversion | 001 | 1 | NIH | 2/6/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | F31DA065365 | Serotonin and dopamine dynamics during kappa opioid mediated aversion | 000 | 1 | NIH | 2/6/2026 | $46,412 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01DK142904 | Estrogen across the menstrual cycle for females with inflammatory bowel disease | 000 | 1 | NIH | 3/20/2026 | $782,361 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R35GM161276 | Mechanisms and Predictions of Interindividual Variability in Drug Pharmacokinetics and Adverse Drug Reactions | 000 | 1 | NIH | 3/20/2026 | $388,750 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | F32GM163495 | Pain State Modulation of Emergence from Anesthesia | 002 | 1 | NIH | 5/12/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | F32GM163495 | Pain State Modulation of Emergence from Anesthesia | 001 | 1 | NIH | 5/12/2026 | $1,248 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | F32GM163495 | Pain State Modulation of Emergence from Anesthesia | 000 | 1 | NIH | 2/20/2026 | $78,052 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01NS143223 | Identifying mechanisms of axon length-dependent degeneration | 000 | 1 | NIH | 4/21/2026 | $502,070 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01GM155536 | Development of Smoldyn | 000 | 1 | NIH | 4/27/2026 | $317,439 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | F32DA065331 | Associations among Daily Social Anxiety, Self-Regulation Dimensions, and Cannabis Use Outcomes in Young Adults Who Engage in Frequent Cannabis Use | 001 | 1 | NIH | 3/25/2026 | $1,248 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | F32DA065331 | Associations among Daily Social Anxiety, Self-Regulation Dimensions, and Cannabis Use Outcomes in Young Adults Who Engage in Frequent Cannabis Use | 000 | 1 | NIH | 2/20/2026 | $78,169 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01HD119026 | Sex differences in allelic gene regulation in human placenta | 000 | 1 | NIH | 6/11/2026 | $564,830 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | K01OD038415 | MAP2K2 in influenza virus-induced acute lung injury and resolution | 000 | 1 | NIH | 6/24/2026 | $122,769 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01AI194419 | Protective efficacy and immunogenicity of a live attenuated Chlamydia strain | 000 | 1 | NIH | 6/10/2026 | $3,414,775 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | K99DK147773 | Photopatterned mechanical and molecular instruction for disease modeling | 000 | 1 | NIH | 6/19/2026 | $90,000 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R00HD112509 | Developing a National Toolkit for School Resource Officer Policy Implementation | 001 | 3 | NIH | 6/20/2026 | -$248,550 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R00HD112509 | Developing a National Toolkit for School Resource Officer Policy Implementation | 001 | 3 | NIH | 6/20/2026 | $248,550 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | F31HD119974 | Targeting PAK1 Kinase in Neurodevelopmental Disorders | 000 | 1 | NIH | 6/18/2026 | $50,114 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R00HD112509 | Developing a National Toolkit for School Resource Officer Policy Implementation | 000 | 3 | NIH | 6/17/2026 | $248,550 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01DK141693 | Early Ultrafiltration for Patients Initiating Hemodialysis | 000 | 1 | NIH | 2/5/2026 | $773,901 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R21HD118142 | Developmental age specific neuroprotective therapies for perinatal brain injury | 000 | 1 | NIH | 5/15/2026 | $406,020 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01DA065598 | Improving the transition to outpatient opioid use disorder treatment through patient navigation plus remote mHealth adherence support for patients initiated on buprenorphine in the hospital | 000 | 1 | NIH | 5/28/2026 | $668,939 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01HD120335 | Metabolic Regulation of Immune Cell Function at the Maternal Fetal Interface | 000 | 1 | NIH | 5/28/2026 | $672,234 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | F31AI194931 | Targeting the Gut-CNS Axis via Distal Gut-Delivered Short-Chain Fatty Acids to Treat CNS Autoimmunity | 000 | 1 | NIH | 5/28/2026 | $45,521 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | F31AI200452 | Investigating how membrane localization and oligomerization drive OAS1 p46 antiviral activity | 000 | 1 | NIH | 5/20/2026 | $46,463 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | T3555568 | Primary Care Training and Enhancement -- Residency Training in Street Medicine | 00 | 1 | HRSA | 5/14/2026 | $499,967 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R21HD121135 | Optimizing spinal stimulation intensity for gait training in cerebral palsy | 000 | 1 | NIH | 5/20/2026 | $383,200 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | F31HL184420 | Investigating the impact of airborne contaminants on work-related asthma in the cannabis cultivation and processing industry | 000 | 1 | NIH | 7/3/2026 | $47,612 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01HL183263 | Molecular Profiling and Risk Assessment of Preeclampsia Using Cell-Free DNA | 000 | 1 | NIH | 6/26/2026 | $1,697,415 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | U01HG014603 | Population Genomics Screening Network (PGSN) Coordinating Center | 000 | 1 | NIH | 3/7/2026 | $2,114,800 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | UM1MH138543 | High-throughput and Machine Learning Optimization of Fluorescent Sensors for Multiplexed Imaging in vivo | 000 | 1 | NIH | 3/9/2026 | $2,305,031 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01DK140210 | Defining the contributions of hypothalamic microglia and perineuronal nets to obesity pathogenesis | 000 | 1 | NIH | 4/8/2026 | $888,773 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R37CA311356 | The Calm Bladder Study-A Phase 3 multicenter randomized controlled trial to evaluate acupuncture for the management of urinary symptoms in patients with NMIBC undergoing induction intravesical therapy | 000 | 1 | NIH | 7/3/2026 | $705,620 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R34MH143573 | Adapting the "Do More, Feel Better" intervention for older people living with HIV | 000 | 1 | NIH | 5/8/2026 | $699,750 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01HD120114 | Impact of HIV and toxic metals exposure on neurodevelopment at school age | 000 | 2 | NIH | 6/2/2026 | $2,726,584 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01AI194521 | Novel mechanisms to inactivate bacterial adhesins | 000 | 1 | NIH | 5/12/2026 | $777,498 |
| | 2026 | 2026 | UNIVERSITY OF WASHINGTON | 4333 BROOKLYN AVE NE | SEATTLE | WA | 98195-1016 | KING | USA | R01HL185768 | Combining large-scale experiments and modeling to dissect the effect of FIXvariants on secretion, carboxylation, activation and disease | 000 | 1 | NIH | 6/12/2026 | $1,601,223 |
|
